Can receptor context and tumor-antigen anchoring improve selectivity of Fas agonism?
The university offers monospecific and bispecific Fas-targeting antibody technology. It describes recognition of a hypoglycosylated or nonglycosylated Fas form in tested tumor settings and proposes additional tumor-antigen anchoring for selectivity.
Fas signaling can eliminate cells but widespread activation raises safety concerns. The invention therefore focuses on receptor context and tumor localization.
Evidence and methods
The public listing summarizes antibody formats and proposed functional selectivity; the linked 2023 Fas paper supplies peer-reviewed mechanistic context. Full development-stage details require direct PI and tech-transfer confirmation.
Fas formats are publicly disclosed
UC Davis lists monospecific and bispecific antibody approaches.
A PCT application is published
The page lists WO2025/160152 with July 31, 2025 publication date.
Inside the study
Selective Fas agonism
The institutional record describes bispecific formats that pair Fas engagement with a tumor-associated target. The proposed selectivity remains a preclinical engineering question.
Interpretation
The proposed bispecific architecture couples a Fas-binding arm with an ovarian tumor-associated anchor. The listing’s safety language is a technology proposition, not proof of patient safety.
Evidence stage
Published invention listing and application. No approved Fas antibody therapy or human clinical efficacy is established.
Paper and research team
Contributors
Inventors are listed in the linked technology record.